The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast cancer is a devastating disease. Some women with breast cancer undergo surgery to remove the breast and lymph nodes in the axilla (armpit). Unfortunately, surgery of this type is associated with pain both in the days immediately following the operation and in the long term. Pain that continues for more than three months after surgery is known as chronic pain and affects as many as 1/5 to more than ½ of patients having this surgery. Often this pain is of a particular type known as neuropathic pain. There have been studies demonstrating that the intensity of pain after surgery may be related to the likelihood of developing chronic pain. It is important to develop methods to reduce acute pain after breast cancer surgery and to reduce chronic pain for breast cancer survivors.

Pregabalin is a medication used in the treatment of chronic pain. It has been shown to be effective for neuropathic pain. There has also been one study demonstrating its effectiveness in reducing pain after dental extraction. We are interested in determining whether pregabalin taken for 14 days starting the day of surgery will reduce acute (short term) pain and chronic pain from this type of breast cancer surgery.

In order to test ability of pregabalin for the reduction of chronic pain it may be necessary to follow a large number of patients for up to one year after surgery. This may require studying patients in more than one institution. Prior to starting such a large study we are proposing a pilot or preliminary study. This study will follow a smaller group of participants (68) for 6 months. From the pilot study we will determine the effect of pregabalin on acute pain and logistic and statistical information required for the full study. We will randomly assign participants to receive pregabalin or placebo (sugar pills) for twice daily for 14 days starting one hour before surgery. We will monitor the participants' pain at one hour after surgery, 24 hours after surgery, one week, two weeks, three months and six months after surgery. We will also monitor for a number of other parameters such as medication side effects and the need for other pain medications. Recruitment of study participants is expected to take 6-7 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery

NCT00785382

Postoperative Pain

COMPLETED PHASE4

Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain

NCT02240199

Post-mastectomy Pain Syndrome Chronic Post-surgical Pain

COMPLETED PHASE3

Pregabalin and Post-thoracotomy Pain

NCT00663962

Chronic Pain

COMPLETED PHASE4

The Effects of Pregabalin on Postoperative Pain After Cardiac Surgery

NCT01701921

Postoperative Pain

COMPLETED PHASE2/PHASE3

Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica

NCT01391858

Post-operative Pain

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Surgery Post Operative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type ACTIVE_COMPARATOR

Pregabalin

Intervention Type DRUG

75 mg twice a day

B

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

75 mg twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin

75 mg twice a day

Intervention Type DRUG

Placebo

75 mg twice a day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18-60 years of age, ASA I-III undergoing breast surgery with axillary dissection for the treatment of breast cancer will be considered eligible for the study.
* Informed consent for the study will be obtained prior to surgery.

Exclusion Criteria

The following persons will not be considered for inclusion in the study:

* Persons undergoing breast surgery for breast cancer without axillary dissection.
* Persons undergoing cosmetic breast surgery.
* Persons undergoing concurrent breast reconstruction.
* Persons undergoing reconstruction within 12 months of surgery.
* Persons with a history of allergy to gabapentin or pregabalin.
* Persons with a history of allergy to morphine, nonsteroidal antiinflammatory drugs, acetaminophen or oxycodone.
* Persons who are or may be pregnant.
* Persons with a BMI \>40.
* Persons with severe organ dysfunction such as liver and renal failure.
* Persons receiving greater than or equal to 30 mg per day of morphine (or equivalent opioid) for pre-existing pain conditions.
* Persons previously on gabapentin or pregabalin within 3 months of surgery.
* Persons with a history of drug abuse. 13) Persons who are unable to communicate in English.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No